The CDMO outsourcing market will experience a period of growth due to the expansion of the pharmaceutical sector. So selecting a CDMO that is a good fit is critical. …
LBG’s Frank Orlowski will have the opportunity to engage with companies presenting cutting-edge technologies and the latest breakthroughs in the biopharma industry on January 9 – 11 in San Francisco. …
LBG’s Marco Daoura, Principal Consultant, participated in M2D2 IMPACT Cycle 4, advising a minimally invasive vessel occluding surgical device. IMPACT is a 12-week accelerator program that uses a unique one-on-one …
LBG recently announced selection into the M2D2 IMPACT Cycle 4 accelerator program. IMPACT is a 12-week accelerator program that uses a unique one-on-one approach that connects startups with resources for commercialization, …
LBG team members Allen Duplantier, Ph.D., Darrel J. Rezac, Ph.D., Cassidy Cantin, and Amy Noon, Pharm.D., will join thought leaders and experts to discuss the latest ideas and innovations in …
Co-presented by LBG on November 18 at 11 a.m. – 12 p.m. ET. This free, informative webinar will provide insights into BARDA’s preferences, practices, and intentions. Registration is open now. …
Sia Partners accelerates in the Life Sciences sector with the creation of a Life Science Consulting division, focused on supporting pharmaceutical biotech, medical device diagnostic and animal health companies across …
Selection of a CDMO can lead to successful clinical trials, approved NDAs, and product approvals. LBG’s Georgia Sloboda, Managing Director, CMC, and Patrick Falvey, Principal Consultant, who have been invited …
The Cell & Gene Meeting on the Mesa is taking place in Carlsbad, California, on October 11 – 13. Joseph Rininger, Ph.D., Managing Director; Jim Beltzer, Ph.D., Principal Consultant; and …
LBG’s Frank Orlowski, Director, Business Development, has been invited to be a keynote speaker at the Global Bio & Pharma Plaza (GBPP 2022)—one of the biggest pharmaceutical and biopharmaceutical industry …
